カテゴリー： QYResearch, 世界, 医療/バイオ

組換え凝固因子濃縮物のグローバル市場2023年：250IU、500IU、1000IU、2000IU

◆英語タイトル：Global Recombinant Coagulation Factor Concentrate Market Research Report 2023
	◆商品コード：QYR23MA3104 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2023年3月 ◆ページ数：119 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD2,900 ⇒換算￥440,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD4,350 ⇒換算￥661,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD5,800 ⇒換算￥881,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の組換え凝固因子濃縮物市場について調査・分析し、世界の組換え凝固因子濃縮物市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（250IU、500IU、1000IU、2000IU）、用途別セグメント分析（病院、クリニック、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Bayer、Alprolix、Benefix、Idelvion、Lxinity、Rebinyn、Rixubis、CSL、Baxalta、Sanofi、Biogen、Pfizer、Novo Disk、Baxter、Wyeth、北京天坛生物制品股份有限公司、上海莱士、泰邦生物、华兰生物、绿十字（中国）生物制品有限公司などが含まれています。世界の組換え凝固因子濃縮物市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、組換え凝固因子濃縮物市場規模を推定する際に考慮しました。

・組換え凝固因子濃縮物市場の概要
- 製品の定義
- 組換え凝固因子濃縮物のタイプ別セグメント
- 世界の組換え凝固因子濃縮物市場規模：タイプ別分析（250IU、500IU、1000IU、2000IU）
- 組換え凝固因子濃縮物の用途別セグメント
- 世界の組換え凝固因子濃縮物市場規模：用途別分析（病院、クリニック、その他）
- 世界の組換え凝固因子濃縮物市場規模予測（2018年-2029年）
- 組換え凝固因子濃縮物の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 組換え凝固因子濃縮物市場の競争状況およびトレンド

・組換え凝固因子濃縮物の地域別市場規模
- 北米の組換え凝固因子濃縮物市場規模（2018年-2029年）
- アメリカの組換え凝固因子濃縮物市場規模（2018年-2029年）
- ヨーロッパの組換え凝固因子濃縮物市場規模（2018年-2029年）
- アジア太平洋の組換え凝固因子濃縮物市場規模（2018年-2029年）
- 中国の組換え凝固因子濃縮物市場規模（2018年-2029年）
- 日本の組換え凝固因子濃縮物市場規模（2018年-2029年）
- 韓国の組換え凝固因子濃縮物市場規模（2018年-2029年）
- インドの組換え凝固因子濃縮物市場規模（2018年-2029年）
- オーストラリアの組換え凝固因子濃縮物市場規模（2018年-2029年）
- 中南米の組換え凝固因子濃縮物市場規模（2018年-2029年）
- 中東・アフリカの組換え凝固因子濃縮物市場規模（2018年-2029年）

・タイプ別セグメント：250IU、500IU、1000IU、2000IU
- 世界の組換え凝固因子濃縮物のタイプ別販売量（2018年-2023年）
- 世界の組換え凝固因子濃縮物のタイプ別売上（2018年-2023年）
- 世界の組換え凝固因子濃縮物のタイプ別価格

・用途別セグメント：病院、クリニック、その他
- 世界の組換え凝固因子濃縮物の用途別販売量（2018年-2023年）
- 世界の組換え凝固因子濃縮物の用途別売上（2018年-2023年）
- 世界の組換え凝固因子濃縮物の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Bayer、Alprolix、Benefix、Idelvion、Lxinity、Rebinyn、Rixubis、CSL、Baxalta、Sanofi、Biogen、Pfizer、Novo Disk、Baxter、Wyeth、北京天坛生物制品股份有限公司、上海莱士、泰邦生物、华兰生物、绿十字（中国）生物制品有限公司

・産業チェーンと販売チャネルの分析
- 組換え凝固因子濃縮物産業チェーン分析
- 組換え凝固因子濃縮物の主要原材料
- 組換え凝固因子濃縮物の販売チャネル
- 組換え凝固因子濃縮物のディストリビューター
- 組換え凝固因子濃縮物の主要顧客

・組換え凝固因子濃縮物市場ダイナミクス
- 組換え凝固因子濃縮物の業界動向
- 組換え凝固因子濃縮物市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.
Highlights
The global Recombinant Coagulation Factor Concentrate market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Recombinant Coagulation Factor Concentrate is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Recombinant Coagulation Factor Concentrate is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Recombinant Coagulation Factor Concentrate include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL and Baxalta, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Coagulation Factor Concentrate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Coagulation Factor Concentrate.
The Recombinant Coagulation Factor Concentrate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Recombinant Coagulation Factor Concentrate market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Coagulation Factor Concentrate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
北京天坛生物制品股份有限公司
上海莱士
泰邦生物
华兰生物
绿十字（中国）生物制品有限公司
Segment by Type
250 IU
500 IU
1000 IU
2000 IU
Segment by Application
Hopistial
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Coagulation Factor Concentrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Coagulation Factor Concentrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Recombinant Coagulation Factor Concentrate Market Overview
1.1 Product Overview and Scope of Recombinant Coagulation Factor Concentrate
1.2 Recombinant Coagulation Factor Concentrate Segment by Type
1.2.1 Global Recombinant Coagulation Factor Concentrate Market Value Comparison by Type (2023-2029)
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 2000 IU
1.3 Recombinant Coagulation Factor Concentrate Segment by Application
1.3.1 Global Recombinant Coagulation Factor Concentrate Market Value by Application: (2023-2029)
1.3.2 Hopistial
1.3.3 Clinic
1.3.4 Others
1.4 Global Recombinant Coagulation Factor Concentrate Market Size Estimates and Forecasts
1.4.1 Global Recombinant Coagulation Factor Concentrate Revenue 2018-2029
1.4.2 Global Recombinant Coagulation Factor Concentrate Sales 2018-2029
1.4.3 Global Recombinant Coagulation Factor Concentrate Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Coagulation Factor Concentrate Market Competition by Manufacturers
2.1 Global Recombinant Coagulation Factor Concentrate Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Coagulation Factor Concentrate Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Coagulation Factor Concentrate Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Coagulation Factor Concentrate Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Coagulation Factor Concentrate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Coagulation Factor Concentrate, Product Type & Application
2.7 Recombinant Coagulation Factor Concentrate Market Competitive Situation and Trends
2.7.1 Recombinant Coagulation Factor Concentrate Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Coagulation Factor Concentrate Players Market Share by Revenue
2.7.3 Global Recombinant Coagulation Factor Concentrate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Coagulation Factor Concentrate Retrospective Market Scenario by Region
3.1 Global Recombinant Coagulation Factor Concentrate Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Coagulation Factor Concentrate Global Recombinant Coagulation Factor Concentrate Sales by Region: 2018-2029
3.2.1 Global Recombinant Coagulation Factor Concentrate Sales by Region: 2018-2023
3.2.2 Global Recombinant Coagulation Factor Concentrate Sales by Region: 2024-2029
3.3 Global Recombinant Coagulation Factor Concentrate Global Recombinant Coagulation Factor Concentrate Revenue by Region: 2018-2029
3.3.1 Global Recombinant Coagulation Factor Concentrate Revenue by Region: 2018-2023
3.3.2 Global Recombinant Coagulation Factor Concentrate Revenue by Region: 2024-2029
3.4 North America Recombinant Coagulation Factor Concentrate Market Facts & Figures by Country
3.4.1 North America Recombinant Coagulation Factor Concentrate Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Coagulation Factor Concentrate Sales by Country (2018-2029)
3.4.3 North America Recombinant Coagulation Factor Concentrate Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Coagulation Factor Concentrate Market Facts & Figures by Country
3.5.1 Europe Recombinant Coagulation Factor Concentrate Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Coagulation Factor Concentrate Sales by Country (2018-2029)
3.5.3 Europe Recombinant Coagulation Factor Concentrate Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Coagulation Factor Concentrate Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Coagulation Factor Concentrate Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Coagulation Factor Concentrate Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Coagulation Factor Concentrate Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Coagulation Factor Concentrate Market Facts & Figures by Country
3.7.1 Latin America Recombinant Coagulation Factor Concentrate Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Coagulation Factor Concentrate Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Coagulation Factor Concentrate Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Coagulation Factor Concentrate Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Coagulation Factor Concentrate Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Coagulation Factor Concentrate Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Coagulation Factor Concentrate Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Coagulation Factor Concentrate Sales by Type (2018-2029)
4.1.1 Global Recombinant Coagulation Factor Concentrate Sales by Type (2018-2023)
4.1.2 Global Recombinant Coagulation Factor Concentrate Sales by Type (2024-2029)
4.1.3 Global Recombinant Coagulation Factor Concentrate Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Coagulation Factor Concentrate Revenue by Type (2018-2029)
4.2.1 Global Recombinant Coagulation Factor Concentrate Revenue by Type (2018-2023)
4.2.2 Global Recombinant Coagulation Factor Concentrate Revenue by Type (2024-2029)
4.2.3 Global Recombinant Coagulation Factor Concentrate Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Coagulation Factor Concentrate Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Coagulation Factor Concentrate Sales by Application (2018-2029)
5.1.1 Global Recombinant Coagulation Factor Concentrate Sales by Application (2018-2023)
5.1.2 Global Recombinant Coagulation Factor Concentrate Sales by Application (2024-2029)
5.1.3 Global Recombinant Coagulation Factor Concentrate Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Coagulation Factor Concentrate Revenue by Application (2018-2029)
5.2.1 Global Recombinant Coagulation Factor Concentrate Revenue by Application (2018-2023)
5.2.2 Global Recombinant Coagulation Factor Concentrate Revenue by Application (2024-2029)
5.2.3 Global Recombinant Coagulation Factor Concentrate Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Coagulation Factor Concentrate Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer Recombinant Coagulation Factor Concentrate Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Alprolix
6.2.1 Alprolix Corporation Information
6.2.2 Alprolix Description and Business Overview
6.2.3 Alprolix Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Alprolix Recombinant Coagulation Factor Concentrate Product Portfolio
6.2.5 Alprolix Recent Developments/Updates
6.3 Benefix
6.3.1 Benefix Corporation Information
6.3.2 Benefix Description and Business Overview
6.3.3 Benefix Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Benefix Recombinant Coagulation Factor Concentrate Product Portfolio
6.3.5 Benefix Recent Developments/Updates
6.4 Idelvion
6.4.1 Idelvion Corporation Information
6.4.2 Idelvion Description and Business Overview
6.4.3 Idelvion Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Idelvion Recombinant Coagulation Factor Concentrate Product Portfolio
6.4.5 Idelvion Recent Developments/Updates
6.5 Lxinity
6.5.1 Lxinity Corporation Information
6.5.2 Lxinity Description and Business Overview
6.5.3 Lxinity Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Lxinity Recombinant Coagulation Factor Concentrate Product Portfolio
6.5.5 Lxinity Recent Developments/Updates
6.6 Rebinyn
6.6.1 Rebinyn Corporation Information
6.6.2 Rebinyn Description and Business Overview
6.6.3 Rebinyn Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Rebinyn Recombinant Coagulation Factor Concentrate Product Portfolio
6.6.5 Rebinyn Recent Developments/Updates
6.7 Rixubis
6.6.1 Rixubis Corporation Information
6.6.2 Rixubis Description and Business Overview
6.6.3 Rixubis Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Rixubis Recombinant Coagulation Factor Concentrate Product Portfolio
6.7.5 Rixubis Recent Developments/Updates
6.8 CSL
6.8.1 CSL Corporation Information
6.8.2 CSL Description and Business Overview
6.8.3 CSL Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CSL Recombinant Coagulation Factor Concentrate Product Portfolio
6.8.5 CSL Recent Developments/Updates
6.9 Baxalta
6.9.1 Baxalta Corporation Information
6.9.2 Baxalta Description and Business Overview
6.9.3 Baxalta Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Baxalta Recombinant Coagulation Factor Concentrate Product Portfolio
6.9.5 Baxalta Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sanofi Recombinant Coagulation Factor Concentrate Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 Biogen
6.11.1 Biogen Corporation Information
6.11.2 Biogen Recombinant Coagulation Factor Concentrate Description and Business Overview
6.11.3 Biogen Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Biogen Recombinant Coagulation Factor Concentrate Product Portfolio
6.11.5 Biogen Recent Developments/Updates
6.12 Pfizer
6.12.1 Pfizer Corporation Information
6.12.2 Pfizer Recombinant Coagulation Factor Concentrate Description and Business Overview
6.12.3 Pfizer Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Pfizer Recombinant Coagulation Factor Concentrate Product Portfolio
6.12.5 Pfizer Recent Developments/Updates
6.13 Novo Disk
6.13.1 Novo Disk Corporation Information
6.13.2 Novo Disk Recombinant Coagulation Factor Concentrate Description and Business Overview
6.13.3 Novo Disk Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Novo Disk Recombinant Coagulation Factor Concentrate Product Portfolio
6.13.5 Novo Disk Recent Developments/Updates
6.14 Baxter
6.14.1 Baxter Corporation Information
6.14.2 Baxter Recombinant Coagulation Factor Concentrate Description and Business Overview
6.14.3 Baxter Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Baxter Recombinant Coagulation Factor Concentrate Product Portfolio
6.14.5 Baxter Recent Developments/Updates
6.15 Wyeth
6.15.1 Wyeth Corporation Information
6.15.2 Wyeth Recombinant Coagulation Factor Concentrate Description and Business Overview
6.15.3 Wyeth Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Wyeth Recombinant Coagulation Factor Concentrate Product Portfolio
6.15.5 Wyeth Recent Developments/Updates
6.16 北京天坛生物制品股份有限公司
6.16.1 北京天坛生物制品股份有限公司 Corporation Information
6.16.2 北京天坛生物制品股份有限公司 Recombinant Coagulation Factor Concentrate Description and Business Overview
6.16.3 北京天坛生物制品股份有限公司 Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.16.4 北京天坛生物制品股份有限公司 Recombinant Coagulation Factor Concentrate Product Portfolio
6.16.5 北京天坛生物制品股份有限公司 Recent Developments/Updates
6.17 上海莱士
6.17.1 上海莱士 Corporation Information
6.17.2 上海莱士 Recombinant Coagulation Factor Concentrate Description and Business Overview
6.17.3 上海莱士 Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.17.4 上海莱士 Recombinant Coagulation Factor Concentrate Product Portfolio
6.17.5 上海莱士 Recent Developments/Updates
6.18 泰邦生物
6.18.1 泰邦生物 Corporation Information
6.18.2 泰邦生物 Recombinant Coagulation Factor Concentrate Description and Business Overview
6.18.3 泰邦生物 Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.18.4 泰邦生物 Recombinant Coagulation Factor Concentrate Product Portfolio
6.18.5 泰邦生物 Recent Developments/Updates
6.19 华兰生物
6.19.1 华兰生物 Corporation Information
6.19.2 华兰生物 Recombinant Coagulation Factor Concentrate Description and Business Overview
6.19.3 华兰生物 Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.19.4 华兰生物 Recombinant Coagulation Factor Concentrate Product Portfolio
6.19.5 华兰生物 Recent Developments/Updates
6.20 绿十字（中国）生物制品有限公司
6.20.1 绿十字（中国）生物制品有限公司 Corporation Information
6.20.2 绿十字（中国）生物制品有限公司 Recombinant Coagulation Factor Concentrate Description and Business Overview
6.20.3 绿十字（中国）生物制品有限公司 Recombinant Coagulation Factor Concentrate Sales, Revenue and Gross Margin (2018-2023)
6.20.4 绿十字（中国）生物制品有限公司 Recombinant Coagulation Factor Concentrate Product Portfolio
6.20.5 绿十字（中国）生物制品有限公司 Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Coagulation Factor Concentrate Industry Chain Analysis
7.2 Recombinant Coagulation Factor Concentrate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Coagulation Factor Concentrate Production Mode & Process
7.4 Recombinant Coagulation Factor Concentrate Sales and Marketing
7.4.1 Recombinant Coagulation Factor Concentrate Sales Channels
7.4.2 Recombinant Coagulation Factor Concentrate Distributors
7.5 Recombinant Coagulation Factor Concentrate Customers
8 Recombinant Coagulation Factor Concentrate Market Dynamics
8.1 Recombinant Coagulation Factor Concentrate Industry Trends
8.2 Recombinant Coagulation Factor Concentrate Market Drivers
8.3 Recombinant Coagulation Factor Concentrate Market Challenges
8.4 Recombinant Coagulation Factor Concentrate Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 組換え凝固因子濃縮物のグローバル市場2023年：250IU、500IU、1000IU、2000IU(Global Recombinant Coagulation Factor Concentrate Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

組換え凝固因子濃縮物のグローバル市場2023年：250IU、500IU、1000IU、2000IU

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp